COPDX: an update of guidelines for the management obstructive pulmonary disease with a review of recent evidence

Simple item page
dc.contributor.authorAbramson, M.
dc.contributor.authorCrockett, A.
dc.contributor.authorFrith, P.
dc.contributor.authorMcDonald, C.
dc.date.issued2006
dc.descriptionThe document attached has been archived with permission from the editor of the Medical Journal of Australia. An external link to the publisher’s copy is included.
dc.description.abstract• Long-acting β2 agonists are an effective and convenient treatment for chronic obstructive pulmonary disease (COPD), but do not significantly improve lung function. • The long-acting anticholinergic tiotropium, which can be taken once daily, decreases exertional dyspnoea and increases endurance by reducing hyperinflation. • The role in COPD of the combination of a long-acting β2 agonist and a glucocorticoid in a single inhaler remains unclear. • The minimum duration of an effective pulmonary rehabilitation program that includes exercise training is 6 weeks. • Long-term treatment with inhaled glucocorticoids may reduce the rate of decline in lung function, but the effect is small. • Aminophylline should no longer be routinely used in acute exacerbations of COPD. • Non-invasive positive pressure ventilation (NPPV) reduces mortality and hospital stay in patients with acute hypercapnic ventilatory failure; it is also an effective weaning strategy for patients who require intubation. • Further studies are required to clarify the role of NPPV in the long-term management of stable COPD.
dc.description.statementofresponsibilityMichael J Abramson, Alan J Crockett, Peter A Frith and Christine F McDonald
dc.identifier.citationMedical Journal of Australia, 2006; 184(7):342-345
dc.identifier.doi10.5694/j.1326-5377.2006.tb00268.x
dc.identifier.issn0025-729X
dc.identifier.issn1326-5377
dc.identifier.urihttp://hdl.handle.net/2440/22745
dc.language.isoen
dc.publisherAustralasian Med Publ Co Ltd
dc.source.urihttp://www.mja.com.au/public/issues/184_07_030406/abr10742_fm.html
dc.subjectHumans
dc.subjectAsthma
dc.subjectPulmonary Disease, Chronic Obstructive
dc.subjectScopolamine Derivatives
dc.subjectAdrenergic beta-Agonists
dc.subjectBronchodilator Agents
dc.subjectExpectorants
dc.subjectDrug Combinations
dc.subjectGlucocorticoids
dc.subjectDiagnosis, Differential
dc.subjectRespiratory Function Tests
dc.subjectVaccination
dc.subjectAdministration, Inhalation
dc.subjectAdministration, Oral
dc.subjectRisk Factors
dc.subjectEvidence-Based Medicine
dc.subjectSocial Support
dc.subjectAustralia
dc.subjectPractice Guidelines as Topic
dc.subjectTiotropium Bromide
dc.titleCOPDX: an update of guidelines for the management obstructive pulmonary disease with a review of recent evidence
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl22745.pdf
Size:
310.55 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

General Practice publications